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Abstract Purpose: (1) To evaluate,
in a non-randomized, institutional,
prospective study, the efficacy of
photodynamic therapy with Visu-
dyne (PDT) in neovascular age-
related macular degeneration 
(AMD) eyes with chorioretinal 
anastomoses (CRA). (2) To review,
in a retrospective study and for 
comparison, the natural evolution 
of neovascular AMD eyes with
CRA. Methods: Prospective clinical
and angiographic study of 17 con-
secutive eyes with CRA, treated 
with PDT. Retrospective clinical and
angiographic study of the natural
course of 17 consecutive patients
with CRA. Masked best-corrected
visual acuity (VA) and angiographic
features at baseline and during the
period of one year were evaluated.
Results: The two groups presented
similar characteristics at baseline re-
garding age, sex, initial VA, duration
of follow-up and angiographic fea-
tures. PDT-treated eyes showed, at 
1-year follow-up, VA stabilization 
or improvement in 73.3% of the
eyes, no cases with very severe VA
loss, and no fluorescein leakage in
46.6% of the eyes. In contrast, at 
1-year follow-up the natural evolu-
tion of CRA was characterized by
severe or very severe VA loss in
69% of the eyes and statistically 
significant mean VA loss (P=0.001)
with persistence of fluorescein leak-
age in all cases. Conclusion: The
natural history of AMD eyes with
CRA leads to progressive and 
dramatic VA loss, which is associated
with blindness in most of the cases.
PDT with verteporfin can offer some
benefit to these patients, allowing
VA stabilization or improvement in
more than two thirds of the cases, at
one year.
Graefe’s Arch Clin Exp Ophthalmol
(2004) 242:368–376
DOI 10.1007/s00417-003-0844-0
C L I N I C A L  I N V E S T I G AT I O N
Rufino M. Silva
José R. Faria de Abreu
António Travassos
José G. Cunha-Vaz
Stabilization of visual acuity 
with photodynamic therapy in eyes 
with chorioretinal anastomoses
Introduction
Chorioretinal anastomoses (CRA), in eyes with age-re-
lated macular degeneration (AMD), have been associat-
ed with different designations, such as deep retinal vas-
cular anomalous complex or retinal angiomatous prolif-
eration [1, 2, 3, 4, 7, 10]. Cases of CRA are considered
to make up as much as 10–15% of the newly diagnosed
cases of neovascular age-related macular degeneration
(AMD). Differentiation of this particular form of AMD
has not been carried out in most clinical trials on AMD.
No proven treatment exists to date [7, 10].
Clinicopathological [4], clinical and angiographic fea-
tures suggesting the presence of CRA [7] have been ex-
tensively described. More recently, different stages of
evolution were proposed [10]. We have chosen, for our
studies, the characterization of these lesions proposed by
Slakter [7] (Table 1).
Natural evolution is thought to be associated, in al-
most every case, with significant decrease in visual acui-
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ty, fibrosis and atrophy. Indocyanine-green-guided laser
photocoagulation (ICG-guided laser) of the “hot spots”
has shown poor results in these eyes [3]. Recently, a
number of oral reports have suggested that photodynam-
ic therapy (PDT) with Visudyne may be of value for the
treatment of CRA, but no prospective studies have been
published.
The purpose of this study was: (1) to evaluate, in a
non-randomized, institutional, prospective study, the ef-
ficacy of PDT with Visudyne in neovascular AMD eyes
with CRA; (2) to review the natural evolution of neovas-
cular AMD eyes with CRA in a retrospective compara-
tive study.
Patients and methods
A prospective institutional study was performed in 17 consecutive
patients, observed after January 2000, with exudative AMD and
CRA who were treated with PDT with Visudyne. PDT treatments
were performed within 3-month intervals, using the standard pro-
tocol of VIP (verteporfin in PDT) and TAP (treatment of AMD
with PDT) trials [8, 9]. Retreatments were applied if fluorescein
angiography showed any leakage from the neovascular lesion,
causing VA decrease.
A retrospective comparative study was carried out, for compar-
ison, in 17 consecutive patients with neovascular AMD and CRA.
All patients in both series were older than 50 years of age at
the time of diagnosis and presented signs of AMD. Only patients
with 6 or more months of follow-up were considered for the stud-
ies.
The criteria for diagnosis of CRA were based on Slakter’s [7]
descriptions and are summarized in Table 1. We considered the
possibility that biomicroscopic and red-free findings suggested the
presence of CRA when intraretinal or preretinal small hemor-
rhages and intraretinal edema (cystoid or not) were associated
with two or more additional features (Table 1). Fluorescein angi-
ography (FA) and indocyanine-green video-angiography (ICG)
were highly suggestive of CRA when early and/or late focal “hot
spots” were present and associated with one or more additional
findings (Table 1). Definitive CRA was assumed only when posi-
tive signs were identified on biomicroscopy and red-free photog-
raphy and with at least one of the two photographic techniques.
Lesions were ≤5400 µm in size (greatest linear dimension) in all
cases at the time of diagnosis.
Cases with disciform scars in the study eye or with other fun-
dus diseases associated with choroidal neovascularization (CNV),
such as angioid streaks, juxtafoveal telangiectasias type 2, myopia,
trauma and intraocular infection or inflammation, were excluded
in both prospective and retrospective studies.
Stereo color and red-free fundus photographs and stereo fluo-
rescein and digital ICG angiograms obtained with the Topcon Im-
age Net system were reviewed in all cases in the two series by two
independent reviewers (R.M.S., J.R.F.A.) and any disagreement
was resolved by a third reviewer (J.G.C.V.).
In both series, VA was tested by a masked observer using the
Early Treatment of Diabetic Retinopathy Study (ETDRS) chart;
the best-corrected VA was obtained in all patients. The evolution
of VA was classified in three groups: 1- VA improvement (moder-
ate: <3 lines, and significant: ≥ 3 and ≤ 6 lines); VA stabilization
(VA change ≤ to 1 line); and VA decrease (moderate: <3 lines, se-
vere: ≥3<6 lines, and very severe: ≥6 lines).
Student’s t-test (differences between means) and MedCalc
(comparison of proportions for percentages) were used for statisti-
cal analysis.
No significant differences between the two groups were found
at baseline in age (P=0.4, Student’s t-test), sex (P=0.3, Student’s
t-test), initial VA (P=0.19, Student’s t-test), follow-up period
(P=0.4, Student’s t-test) or angiographic features (Tables 2, 3 and
4).
Table 1 Criteria for characterization of CRA: biomicroscopy,
photographic and angiographic features suggesting the presence of
CRA in exudative AMD eyes
Biomicroscopy and stereo FA and ICG
red-free photography
Intra or preretinal hemorrhages Leakage at retinal level
or retinal edema
Dilated retinal vessels √
Retinal–retinal anastomosis √
Ring of lipid exudates and PED √
Sudden termination of dilated √
and/or tortuous “going-down” 
retinal vessel
FA and/or ICG hot spots
(not due to PE atrophy)
Chorioretinal anastomoses
Two-tier angiographic 
complex6 on ICG
Table 2 Results of prospective and retrospective studies at 1 year. (P difference between initial VA and VA at 3, 6 and 12 months)
n Age VA VA improvement VA VA loss
(years) stabili-
Initial At At At ≤6≥3 <3 zation Moderate Severe Very 
3 months 6 months 12 months lines (%) lines (%) (%) (%) (%) severe 
(%)
Natural 13 74.5 20/105 20/245 20/311 20/329 0 0 7.6 30.7 30.7 38.3
evolution, 
1 year P=0.01 P=0.003 P=0.001
Prospective 15 74.6 20/149 20/169 20/149 20/137 20 0 53.3 20 20 0
study 
(PDT), 
1 year P=0.3 P=0.4 P=0.4
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Table 3 Results of PDT treatment in AMD eyes with CRA (NLP no light perception)
Patient Age (years)/ Follow-up VA change (lines) Initial VA of Number of Leakage at 
sex (months) VA other eye treatments last observation
At At At 
3 months 6 months 12 months
1 78/F 12 −9 −9 −5 20/32 20/160 3 No
2 71/M 6 −1 −1 – 20/40 20/25 3 Yes
3 79/F 15 0 0 0 20/200 20/800 4 Yes
4 77/F 12 0 0 0 20/200 20/800 1 No
5 77/M 21 1 −1 −2 20/40 20/63 1 No
6 75/M 12 0 −1 −1 20/40 20/40 3 No
7 75/M 6 1 1 – 20/200 20/25 3 Yes
8 50/M 12 0 0 0 20/50 20/20 5 Yes
9 86/F 12 0 0 0 20/200 20/800 4 No
10 78/F 24 −1 −4 −3 20/25 20/640 7 Yes
11 72/F 12 −4 −5 −4 20/100 20/800 5 Yes
12 76/F 18 0 3 3 20/800 20/800 3 No
13 71/F 24 0 3 3 20/80 20/800 8 Yes
14 78/F 15 0 0 0 20/200 20/1600 2 No
15 76/F 12 0 0 0 20/50 NLP 4 Yes
16 76/F 18 0 1 3 20/200 20/800 6 No
17 74/F 30 0 −1 −1 20/80 20/800 8 Yes
Table 4 Natural evolution of
AMD eyes with CRA Patient Age (years)/ Follow-up VA change (lines) Initial VA VA of 
sex (months) other eye
At At At 
3 months 6 months 12 months
1 81/M 12 −3 −3 −3 20/200 20/160
2 70/F 6 −3 −7 – 20/25 20/800
3 78/F 15 0 0 −1 20/160 20/160
4 81/M 12 −10 −10 −10 20/80 20/25
5 69/F 24 −1 0 −2 20/25 20/800
6 77/F 12 0 0 −3 20/400 20/40
7 75/M 6 0 0 − 20/200 20/25
8 85/F 12 −3 −4 −4 20/80 20/800
9 60/F 9 −0 −1 – 20/25 20/20
10 80/F 24 −12 −12 −8 20/32 20/800
11 75/M 12 −3 −3 −7 20/80 20/800
12 77/F 18 −3 −15 −7 20/40 20/400
13 74/F 30 −4 −4 −7 20/100 20/500
14 81/M 15 −3 −6 −5 20/200 20/25
15 77/M 6 −4 −4 – 20/63 20/25
16 56/F 36 0 0 −2 20/40 20/500
17 72/F 30 −1 −1 −2 20/50 20/800
Results
Prospective study: photodynamic therapy
Seventeen eyes of 17 patients, 11 women and 6 men,
with an average age of 74.64 years (range 50–86) were
treated with PDT with Visudyne. Mean follow-up period
was 15.3 months (range 6–36) and mean number of PDT
sessions was four (range one to eight).
All the patients were observed at 3 and 6 months. Fif-
teen patients were observed at 1 year follow-up. The
mean initial VA was 20/149 (20/800–20/25) and the
mean final VA was 20/141 (20/320–20/50). The differ-
ence between initial VA and VA at 1 year was not statis-
tically significant (P=0.4, Student’s t-test) (Tables 2, 3,
4), indicating stabilization. The ICG hot spots were ex-
trafoveal in 88.2% of the eyes at initial observation.
VA stabilization or improvement was present in
88.2% and 82.4% of the eyes at 3 and 6 months, respec-
tively. Severe or very severe VA loss had occurred in
11.8% and 17.6% of the eyes at 3 and 6 months respec-
tively. Fifteen patients were observed at 12 months. Sta-
bilization or improvement of VA was found in 73.3% of
the eyes and severe VA loss had occurred in 20% of the
eyes. VA improvement was present in 11.8% of the eyes
at 6 months and in 20% at 12 months (Table 2).
No foveal exudation was present at 1 year in 46.6% of
the eyes and no PDT was performed at that time. Two
eyes presented recurrence of exudation after two or more
consecutive observations with no FA leakage and no
PDT treatment and 12 or more months of follow-up (cas-
es 3, 17).
In 64.7% of the patients, the VA of the contralateral
eye was ≤20/200 (Table 3). Disciform scars with retinal
chorioretinal anastomoses were present in all of them.
One of the contralateral eyes also had a central retinal ar-
tery occlusion. Pigment epithelium detachment (PED)
documented with FA and ICG was present in 64.7% of
the eyes at the time of diagnosis.
No PED rip or preretinal, intraretinal or subretinal ex-
tensive hemorrhages occurred in the treated eyes.
Retrospective study: natural evolution
A retrospective study of the natural evolution of 17 con-
secutive eyes with AMD and CRA was performed on 17
patients, 11 women and 6 men, with an average age of
74.5 years (range 56–85) and a mean follow-up period of
16 months (range 6–36), beginning at the time of diagno-
sis. All the patients were observed at 3 and 6 months,
and 13 patients were observed at 1 year. An extrafoveal
hot spot on ICG was predominant (82.3%) at the time of
diagnosis.
VA stabilization or improvement occurred in 58.8%
of the eyes and severe or very severe VA loss occurred in
41.2% at 3 and 6 months. At 1 year, VA stabilization was
present in only 7.6% of the eyes and severe or very se-
vere VA loss had occurred in 69% of the eyes. The con-
tralateral eye of 52.9% of the patients, presented, at the
time of enrolment, a VA of ≤20/400 and disciform scars
with retinal choroidal anastomoses (Table 4).
At 3 and 6 months, there was no significant difference
in the proportion of eyes with visual loss in both series,
but at 12 months, the proportion of eyes with visual loss
was 26.7% in the PDT group vs 92.3% in the natural his-
tory group (P=0.003).
Discussion
Our study evaluates the efficacy of PDT in AMD eyes
with CRA compared with the natural course of the dis-
ease. We have found that PDT stabilizes VA in eyes with
CRA until one year of follow-up, offering, therefore, a
better alternative. As far as we know, no previous reports
have been published on this subject.
CRA, a subcategory of exudative AMD is a relatively
well defined entity. The diagnosis of CRA can be sus-
pected by an expert physician, using only biomicroscopy
and red-free photography. For this study, we used well-
defined objective criteria (Table 1). FA and particularly
ICG were used for confirmation of the diagnosis. A de-
finitive diagnosis of CRA was only performed when pos-
itive features were present on biomicroscopy, red-free
photography and at least one of the two different an-
giograms, FA and ICG.
Our study has one important limitation, namely that it is
based on a comparison between prospective and retrospec-
tive analyses. However, the similarity between the two
groups regarding age, sex, initial VA, follow-up period,
and angiographic features reduces the confounding factors
that may have influenced the outcome (Tables 3 and 4).
Females, who are generally more affected than males
[7, 10], represented, in our series, 64.7% of the patients
of the PDT and natural evolution groups. The marked
tendency to severity, bilateral and symmetry of manifes-
tations of the disease [7, 10] was also present in the two
series (Tables 3 and 4). 64.7% and 52.9% of the patients
of the PDT and natural evolution, respectively, presented
manifestations of the disease in the contralateral eye as-
sociated with a VA ≤20/200.
The natural evolution group showed, at 12 months,
VA stabilization in 7.6% of the eyes and VA loss in
92.3%. The VA decrease was severe or very severe in
69.2%. No eyes had VA improvement and in 76.9% VA
was ≤20/200 at 1 year. The poor outcome of the natural
evolution group was already expected at the 3-month fol-
low-up, when 58.8% of the eyes presented severe or very
severe VA decrease (compared with only 11.7% of the
PDT group eyes at the same duration of follow-up). At
the end of the follow-up the mean VA decrease of the
natural evolution group was statistically significant
(P=0.002); 70.5% of the eyes were legally blind and all
the eyes presented subfoveal leakage of fluorescein.
Therefore, the natural course of CRA eyes appears to be
characterized by severe or very severe VA loss in the
first 3–6 months in nearly half of the eyes as in our se-
ries (Fig. 1). Additional VA loss occurs in the following
months, with at least two thirds of the eyes becoming
legally blind, with no treatment, in a mean period of 16.4
months. Leakage on FA persists for months or years and
the initial lesion is progressively being replaced by fi-
brous tissue. The most common end stage is a disciform
scar with multiple retinal choroidal anastomoses.
Eyes with CRA that we treated with PDT showed bet-
ter results than those that followed the natural course. At
1 year, the PDT-treated eyes showed VA stabilization or
improvement in 73.3% of the eyes and absence of sub-
foveal fluorescein leakage in 46.6% of the eyes. The best
VA results, compared with natural evolution, were seen
at 3 months (only 11.7% of the eyes with severe or very
severe VA loss) and at 6 months (17.6% of the eyes with
severe or very severe VA loss). After a mean follow-up
of 15.3 months, no eyes experienced very severe VA
loss, with 35.3% of the eyes maintaining final VA of
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Fig. 1a, b Natural evolution of
CRA: case 2. a Baseline imag-
es. Intraretinal hemorrhages
and hard exudates on red-free
images and two hot spots on
early and late ICG are visible.
VA is 20/25. b Three months
later VA is 20/50, a ring of lip-
id exudation is visible, intraret-
inal hemorrhages are bigger,
and ICG shows two hot spots
and PED
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Fig. 2a–f Legend see page 374
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Fig. 2a–k Case 15: stage 2 CRA before and after PDT. a, b Red-
free and color photographs: a ring of lipid exudates, neurosensory
detachment, intraretinal small hemorrhages. c, d FA, early and late
phases. Serous PED with a “hot spot” (not due to pigment epithe-
lium atrophy); small hemorrhages at the retinal level and exten-
sion of leakage to the retina. e, f ICG, early and late phases. Large
PED and macular hot spot. g–k At 6 months after the diagnosis,
following two PDT treatments. A clear improvement is noted with
some reabsorption of lipid exudation and progressive replacement
of angiomatous mass by fibrotic tissue. FA shows minimal leakage
and more staining. On ICG subretinal neovascularization is less
active and no PED is observed
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≥20/63; 70.5% of the eyes showing VA stabilization or
improvement, and no leakage being present in 47% of
the eyes at the final observation.
The selection of the spot size for PDT may be a con-
troversial issue. The ICG hot spot would probably indi-
cate the size of the lesion. ICG and verteporfin share
some properties; they have the same molecular weight
and the same affinity to bind with proteins. It could be
speculated that verteporfin will stain only what ICG
stains, because of the similar characteristics of the two
substances. However, similar leaking and staining prop-
erties of both ICG and verteporfin have not yet been con-
firmed. No pooling of ICG occurs in serous PED, and
probably no pooling of verteporfin will occur either. It
has therefore been proposed that the spot size for PDT
should be the same size as that of the hyperfluorescence
seen on ICG. However, we have chosen to treat the le-
sion with the size visualized on FA (largest diameter plus
1 mm) because there is no experience of ICG-guided
PDT, and verteporfin has not yet been successfully im-
aged with good specific resolution in humans [6]. Our
decision is also based on our experience in treating hot
spots with laser photocoagulation. In many treated cases,
the ICG control at 2–3 weeks showed hyperfluorescence
at the border of the scar after the laser photocoagulation.
At the beginning, this was assumed to be caused by the
persistence of the neovascularization. With retreatment,
a new hyperfluorescence was visible. The digital overlay
showed that all the initial lesions had been treated during
the first and second treatment. We may speculate that
with laser photocoagulation, some flattening of PED
may occur near the scar and partial visualization of CNV
is possible. One of these patients was later submitted to
surgery and a CNV with the same size as the PED was
excised. The masking effect of the serous PED probably
prevented the visualization of CNV on ICG.
During follow-up, some of the treated eyes developed
a classic CNV component. The role of PDT in this evo-
lution cannot be ruled out. However, identical behavior
has been described in natural evolution of subfoveal
CNV [5, 6, 8, 9]. In our series, PDT achieved a progres-
sive closure of this classic CNV component.
Some arguments have been put forward suggesting
that eyes with CRA should not be treated with PDT. One
reason is the possibility of intraretinal ICG leakage in
some CRA eyes and an expected similar behavior with
verteporfin. Neurosensory damage would occur with
PDT. Another reason is related to the possibility of PED
rip with PDT. In most of the cases, the intraretinal or
subretinal leakage documented on ICG is extrafoveal or
juxtafoveal. PDT can be useful in these cases, before
progression of the lesion to the subfoveal space. This
benefit may be greater than the potential neurosensory
damage. PED rips have also been described to occur as a
result of PDT or laser photocoagulation [5]. No cases of
PED rip developed in our series.
PDT-treated eyes showed a variable response to the
treatment. In some eyes, after the first or second treat-
ment, the ICG hot spot became larger, a classic compo-
nent of the lesion became apparent or bigger on FA, and
VA decreased. Over time, leakage decreased on FA, se-
rous PED became flatter, the ICG hot spot became atten-
uated or disappeared, and the lesion became progressive-
ly atrophic and/or fibrotic. An extrafoveal scar progres-
sively developed with stabilization of VA (Fig. 2). Eyes
with larger PED seemed to be associated with a worse
prognosis. In other eyes (e.g., cases 3, 17), recurrence
occurred after a period of 6 months or more without
treatment. In these eyes ICG hot spot was present during
the whole follow-up, even in the absence of fluorescein
leakage. The importance of this feature is difficult to
evaluate due to the small number of cases and the persis-
tence of plaque or focal hyperfluorescence in eyes show-
ing no recurrences.
In conclusion, AMD eyes with CRA showed a natural
course towards very severe VA loss and blindness. Our
study suggests that PDT with verteporfin can offer some
benefit to AMD eyes with CRA, allowing VA stabiliza-
tion or improvement in more than two thirds of the eyes,
and absence of leakage in nearly half of the eyes at one
year. Larger prospective studies and identification of
CRA eyes in randomized clinical trials will certainly of-
fer new insights into the treatment of this particular form
of AMD.
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